Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo

Parisa Sinai, Rance E. Berg, J. Marshall Haynie, Merrill J. Egorin, Robert L. Ilaria, James Forman

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Imatinib mesylate (IM) is effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia. Because its influence on CD8 T cell responsiveness in vivo is unknown, we investigated the effects of IM by analyzing the response of OT-1 CD8 T cells to Listeria monocytogenes (LM) that express the cognate epitope OVA257-264 (LM-OVA). In vitro, IM had no effect on Ag-specific expansion, cell division, cell cycle progression, or IFN-γ expression in naive or memory OT-1 T cells. However, IM induced apoptosis of naive and memory OT-1 T cells at doses of >5 μM. At 15 μM IM, OT-1 T cells did not survive in in vitro cultures. The primary response of OT-1 T cells in vivo to LM-OVA infection was unaltered. In contrast, continuous IM treatment resulted in a diminished memory OT-1 response. The expression of IL-7Rα, a receptor required for memory cell survival, was lower (on OT-1 cells) in animals receiving IM. These results indicate that IM treatment affects the ability of the CD8 memory pool to respond to Ag and has the potential to increase susceptibility to infection.

Original languageEnglish
Pages (from-to)2028-2037
Number of pages10
JournalJournal of Immunology
Issue number4
StatePublished - 15 Feb 2007


Dive into the research topics of 'Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo'. Together they form a unique fingerprint.

Cite this